Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2009 Sep;39(9):619-23.
doi: 10.1111/j.1445-5994.2009.01996.x.

Fluoroquinolone-induced immune thrombocytopenia: a report and review

Affiliations
Review

Fluoroquinolone-induced immune thrombocytopenia: a report and review

C Y Cheah et al. Intern Med J. 2009 Sep.

Abstract

Fluoroquinolones are an emerging but underrecognized cause of drug-induced thrombocytopenia. Due to their broad spectrum they are often used in empirical treatment of febrile neutropenic, thrombocytopenic patients following myelosuppressive chemotherapy. They are associated with a range of immunohaematopathology. A 76-year-old male developed severe thrombocytopenia following treatment with ciprofloxacin on two occasions for community-acquired pneumonia. The temporal association, response to dechallenge, dramatic response to rechallenge and exclusion of other causes combined with detection of platelet-reactive antibodies of the immunoglobulin G class against glycoprotein IIb/IIIa following ciprofloxacin rechallenge makes causality probable. We present a brief review of immunohaematopathology associated with fluoroquinolones and draw attention to the structural similarity between quinolones and quinine to explore potential mechanisms for the phenomenon. Fluoroquinolones can induce drug-dependent, platelet-reactive antibodies causing complement-mediated destruction of platelets. The underlying mechanism to explain this is unclear; however, we hypothesize that the chemical similarities shared with quinine may be contributory. When using these agents clinicians should be aware of the possibility of drug-induced thrombocytopenia or thrombotic thrombocytopenic purpura.

PubMed Disclaimer

Substances

LinkOut - more resources